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Background: Retinitis Pigmentosa (RP) is a hereditary genetic disease causing bilateral retinal degeneration. RP is a
leading cause of blindness resulting in incurable visual impairment and drastic reduction in the Quality of life of the
patients. Second Sight Medical Products Inc. developed Argus II, a retinal prosthesis system for treating RP. Argus II
is the world’s first ever-commercial implant intended to restore some vision in the blind patients. The objective of
this study was to assess the cost-effectiveness of the Argus® II Retinal Prosthesis System (Argus II) in Retinitis
Pigmentosa (RP) patients.
Method: A multi -state transition Markov model was developed to determine the cost-effectiveness of Argus II
versus usual care in RP from the perspective of healthcare payer. A hypothetical cohort of 1000 RP patients aged 46
years followed up over a (lifetime) 25-year time horizon. Health outcomes were expressed as quality adjusted life
years (QALYs) and direct healthcare costs expressed in 2012 €. Results are reported as incremental cost per ratios
(ICERs) with outcomes and costs discounted at an annual rate of 3.5%.
Results: The ICER for Argus II was €14,603/QALY. Taking into account the uncertainty in model inputs the ICER was
€14,482/QALY in the probabilistic analysis. In the scenarios of an assumption of no reduction on cost across model
visual acuity states or a model time horizon as short as 10 years the ICER increased to €31,890/QALY and €49,769/
QALY respectively.
Conclusion: This economic evaluation shows that Argus II is a cost-effective intervention compared to usual care of
the RP patients. The lifetime analysis ICER for Argus II falls below the published societal willingness to pay of
EuroZone countries.
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Retinitis Pigmentosa (RP) is a leading cause of blindness
resulting in incurable visual impairment [1]. It is a heredi-
tary genetic disease causing bilateral retinal degeneration.
It predominantly affects the photoreceptors of the retina
and causes progressive loss of vision eventually leading
to blindness. The prevalence of RP is estimated to be
about one in 4000 affecting over one million individuals
worldwide [2]. RP is usually diagnosed in young adult-
hood, although it can present any time from infancy to* Correspondence: a.vaidya@maastrichtuniversity.nl
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unless otherwise stated.the mid-30s to 50s. Most people who have RP are legally
blind by the age of 40.
Visual deficiency results in a significant economic and
social disadvantage in affected individuals, their families,
and society in general. Patients with a visual deficiency
have more frequent medical visits, and many need assist-
ance to perform daily life activities. RP results in a drastic
reduction of the quality of life in affected individuals. In
patients who have lost their sight: admission to nursing
homes occurs three years earlier; the probability of falling
is two times higher, the incidence of depression is three
times higher; hip fractures are four times more common
and the likelihood of death is twice as compared to the
general population of the same age [3,4].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Degeneration (AMD) International Alliance, blindness
and visual impairment cost the world economy nearly
2.3 trillion euros in 2010. This estimate considers the
direct medical expenses for the 733 million blind or se-
verely visually impaired people all over the world, but
also the value of the time dedicated to caring for them
and the loss of productivity, resulting in a loss of tax
revenues that sustain the healthcare systems [5]. That
means nearly 6 billion euros for the 1, 75 million af-
fected by RP [5].
There is no treatment that can restore the functional
vision or ensure regression or prevention of visual loss.
Education, awareness of the disease, genetic advice and
rehabilitation are used in regular practice to cope with
the social and psychological impact of RP [6]. Ad-
vanced RP is associated with blindness and these pa-
tients are given independent living rehabilitation and
vocational rehabilitation to promote independence and
to prevent injury. Care for these patients also include
formal and informal nursing care.
A retinal prosthesis placed on the retinal surface has
been investigated for several years. The healthy ganglion
cell layer of the retina can be stimulated by using retinal
prosthesis and these implants in animal models have long-
term stability [7]. Humayun et al. demonstrated the use of
retinal prosthesis in human subjects [8]. Currently these
retinal prostheses represent the basis for further studies
towards improvement of the future devices resolution.
Second Sight Medical Products Inc. developed Argus
II, a retinal prosthesis system for treating RP. Argus II
is the world’s first ever-commercial implant intended
to restore some vision in the blind patients. Argus II is
an implantable device that works by converting video
images captured from a miniature camera, housed in
the patient’s glasses, into a series of small electrical im-
pulses that are transmitted wirelessly to an array of
electrodes on the surface of the retina. It has improved
the visual function of patients, from minimal light
perception to at least the perception of hand motions,
even counting fingers. Patients can locate and recognize
simple objects, see people in front of them, and follow
their movement [9]. It is the world’s first and only device
that has received both CE-mark and FDA approval
intended to restore some functional vision for people suf-
fering from blindness. Argus II is approved for use in the
European Economic Area (CE Mark) and USA (FDA
Approval).
We sought to conduct an economic evaluation of the
Argus II device to inform reimbursement policy deci-
sions and its implementation in usual practice. The aim
of this study was to assess the cost-effectiveness of
Argus II compared to usual care for the treatment of RP
in Eurozone countries.Methods
The study was conducted according to the principles of
good practice for decision analytic modeling according to
the International Society for Pharmacoeconomics and
Outcome Research (ISPOR) task force guidelines [10]. A
cost utility analysis was performed from the healthcare
payer’s perspective for Argus II over the time horizon (life-
time) of 25 years.
The average age of diagnosis of RP is reported to be 35.1
years and median age is 36.5 years [11]. We assumed that
over a decade the visual impairment will progress to the
level of legal blindness in these patients. Therefore, we
simulated a hypothetical cohort of 1000 RP male and fe-
male patients aged 46 years [12].
In our model this cohort was compared to another
hypothetical cohort of usual care RP patients “Care As
Usual” i.e. nursing care, rehabilitation etc.
Model structure
A Markov model with annual cycles was developed with
four health states:
1. RP patients with minimal light perception, MLP
2. Visual acuity + (light perception, LP)
3. Visual acuity ++ (counting fingers, CF)
4. Visual acuity +++ (reading letters, RL)
The model analysis began in the first state (RP patients
with minimal light perception) for all the individuals. The
other three Markov states represent progressive improve-
ment in visual acuity of Argus II fitted patients. The hypo-
thetical cohort fitted with Argus II device was followed up
for the time horizon of the model for their movement into
the other Markov states based on the calculated transi-
tional probabilities. The reference hypothetical cohort
with ‘Care As Usual (CAU)’ remained in the state of RP
patient with minimal light perception for the entire model
time horizon. The decision analytic model was developed
in Microsoft excel 2010 software (Microsoft Corporation,
Redmond, Washington). The schematic diagram of the
Markov model is shown in the Figure 1.
Data sources
1. Transition probabilities
A controlled, non-randomized, prospective, multi-
centric study conducted in 10 sites in Europe and in
the United States, showed the performance and
safety of the Argus II in 30 eligible patients with se-
vere external retinal degeneration caused by RP [13].
The results were systematically analyzed controlling
the system activation (system on versus system off ).
These patients received the Argus II between June
2007 and August 2009. The Functional Low-Vision
Visual Acuity +
LP
Visual Acuity ++
CF
Visual Acuity +++ 
RL
RP patient ± 
Argus II
MLP
Explantation
Figure 1 Markov model.
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low vision test, was developed in the year 2010 by
the company Second Sight Medical Products in col-
laboration with a group of experts specialized in low
vision rehabilitation. The ‘FLORA functional low vi-
sion test’ was completed in April 2011. Three assess-
ment tools were utilized to assess the ARGUS II
subjects namely:
a. In-depth interview of the subject by assessors
b. Observer rated task including orientation,
mobility and day to day activities
c. A case study narrative written by the assessors after
the assessment. This represented the totality of the
assessor’s judgment and opinions about the effects
of the ARGUS II system on patient’s daily life.
The data from 30 eligible RP patients implanted with
the Argus II Retinal Prosthesis were used to calculate
the transition probabilities for our decision analytic
model. The model assumed to have Argus II fitted
patients moving from low visual acuity to higher
visual acuity health states at an annual rate of 10%.
This transition was deemed reasonable after personal
communication with experts. The Markov model
transition probabilities are shown in the Table 1.Costs
The cost of the patient screening for eligibility to Argus II
implant, cost of Argus II device, cost of the surgical pro-
cedure including medications, instruments and supplies,costs of clinical follow-up and rehabilitation and cost of an-
nual upgrade of the device were provided by the implant
manufacturer Second Sight Medical Products Inc. The
costs assigned to each Markov state were taken from an
article published by Frick et al. [14]. In this article, annual
health care cost for RP patients are published for the year
2012. Total mean annual costs per patient were estimated
to be 14,988 USD in United States. These costs were con-
verted to 2012 Eurozone costs by using purchasing power
parity (PPP) from the Organization for Economic Cooper-
ation and Development (OECD) database [15]. The total
mean annual costs for RP patients in the Eurozone were es-
timated to be 11,789 Euros for the year 2012.
An association between the vision loss and increased
risk of injury and depression is reported by Javitt et al.
[16]. Excess costs for eye related and non-eye related med-
ical care associated with blinding eye disease are also re-
ported by the same author [16]. A reduction in RP
patient’s medical and non-medical costs is expected with
improved visual acuity as the result of a decrease in the
frequency of falls, reduction in depression/anxiety and re-
duced need for home care. Cost of care in Age related De-
generation (AMD) has been reported by Hernández-
Pastor et al. [17]. As there is are no robust data available
regarding the reduction in the cost of care for RP patient
with improving visual acuity, on the basis of Hernández-
Pastor’s article we assumed a stepped reduction in cost of
care (assistance from paid professionals for daily activities
and social benefits received for visual disabilities for
Table 1 Model parameters
Name Description Deterministic value Probabilistic components Source
Distribution Range Gamma Alpha1 Alpha 2
Min Max
cDR Cost discount rate 0.035 Fixed Pharmaco economic guidelines (NICE)
oDR Outcome discount rate 0.035 Fixed Pharmaco economic guidelines (NICE)
cArgus II Costs of device + implantation 90800 BETA Pert 68100 113500 8 5 5 Second Sight
cRP Annual health care costs incurred on RP patients 11789 BETA Pert 8841 14736 8 5 5 Frick et al. [14]
cVA+ Annual health care costs incurred on RP patients with VA+ 9431 BETA Pert 7073 11789 8 5 5 Frick et al. [14] + assumption
cVA++ Annual health care costs incurred on RP patients with VA++ 8252 BETA Pert 6189 10315 8 5 5 Frick et al. [14]+ assumption
cVA+++ Annual health care costs incurred on RP patients with VA+++ 7073 BETA Pert 5305 8841 8 5 5 Frick et al. [14] + assumption
cSAE Cost of management of Serious Adverse Event 1000 BETA Pert 750 1250 8 5 5 Expert opinion
cExplant Cost of Explantation 2000 BETA Pert 1500 2500 8 5 5 Humayun et al. [9]/Second sight
cOthers Annual other costs for Argus II patients (e.g. Upgrades etc.) 300 BETA Pert 225 375 8 5 5 Humayun et al. [9]/Second sight
pVA+ Argus II patient’s annual probability of getting VA+ 0.74 BETA Pert 0.554 0.924 8 5 5 Humayun et al. [9]/Second Sight
pVA++ Argus II patient’s annual probability of getting VA++ 0.21 BETA Pert 0.154 0.257 8 5 5 Humayun et al. [9]/Second sight
pVA+++ Argus II patient’s annual probability of getting VA++ 0.04 BETA Pert 0.029 0.049 8 5 5 Humayun et al. [9]/Second sight
pSAE Probability of Serious Adverse Event in Argus II patients in first year 0.3 BETA Pert 0.225 0.375 8 5 5 Humayun et al. [9]/Second Sight
pExplant Argus II patient’s annual probability of device explantation 0.02 BETA Pert 0.013 0.021 8 5 5 Humayun et al. [9]/Second Sight
uRP Utility value in RP patients 0.26 BETA Pert 0.195 0.325 8 5 5 Brown et al. [18]
uVA+ Utility value in RP patients with VA+ 0.35 BETA Pert 0.263 0.438 8 5 5 Brown et al. [18]
uVA++ Utility value in RP patients with VA++ 0.52 BETA Pert 0.39 0.65 8 5 5 Brown et al. [18]
uVA+++ Utility value in RP patients with VA+++ 0.54 BETA Pert 0.405 0.675 8 5 5 Brown et al. [18]
uSAE (dis) utility value in patients with Serious Adverse Events 0.16 BETA Pert 0.12 0.2 8 5 5 Schiffman et al. [19]
uExplant Utility value in patients post Argus II explantation 0.26 BETA Pert 0.195 0.325 8 5 5 Assumption
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tion of 20% for patients with mild visual acuity improve-
ment (light perception), 30% in patients with moderate
visual acuity improvement (counting fingers) and 40% in
patients with good visual acuity improvement (reading
letters).
The costs of serious adverse events were 1000 Euros per
event and the cost of explantation was 2000 Euros in the
model. These costs are based on the actual data of serious
adverse events in FLORA study participants provided by
the Second Sight Medical Products Inc. These cost esti-
mates were also confirmed by experts in the field. This
economic evaluation was conducted from the payer’s per-
spective, so only the direct costs were included. Various
cost estimates used in the model are shown in the model
parameter Table 1.
Utility values and QALYs
Health outcomes were quantified as QALYs. Argus II Ret-
inal Prosthesis is expected to improve the quality of life by
means of improving the visual acuity. Decreased depres-
sion, injury and improved functional vision and self-
dependence would enhance utility for Argus II fitted RP
patients. The measurement of utility values in retinal pros-
thesis for RP patients has not been previously undertaken.
Therefore we used published utility values for the compar-
able patients. Brown et al. has published utility values for
minimal light perception, light perception, counting fingers
and reading letters. These utility values are elicited by using
time trade off method in patients with ocular diseases [18].
Patients who experienced Serious Adverse Events (SAEs)
after the Argus II implantation were assigned a utility re-
duction of 0.16 which is equivalent to the lost utility value
estimated for severe dry eye in an article by Schiffman et al.
[19]. In our model, after explantation of the Argus II device
patients returned to the initial Markov state of ‘ minimal
light perception’ and were assigned the utility value of this
state i.e. 0.26. The utility values used in the model are
shown in the model parameter Table 1.
Data analysis
Cost effectiveness results are expressed as incremental cost
effectiveness ratios i.e. incremental cost per QALY. We dis-
counted costs and QALYs at an annual rate of 3.5% [20].
Sensitivity analysis
We conducted Probabilistic Sensitivity Analysis (PSA) to
account for underlying uncertainty in model inputs. Monte
Carlo simulation was performed to assess the precision of
cost effectiveness estimates. (in a PSA, each parameter is
given a probability distribution, and uncertainty in all
model parameters is then explored simultaneously using
1000 Monte Carlo simulation). In each of the iteration,
Model parameters were randomly sampled across theirrespective distribution range. Model parameters were
assigned Beta Pert probability distribution to capture
the uncertainty. The BETA Pert distribution for model
parameters (based on mode and ±25% range) was used
as confidence intervals or standard errors were not re-
ported in the source literature. The reported determin-
istic values were varied in ±25% range to calculate the
minimum and maximum for BETA Pert distribution.
Net Monetary Benefit (NMB) framework expressing the
net benefit of each strategy in monetary terms is applied
to our cost effectiveness results [21]. A positive net monet-
ary benefit implies that the cost of a new therapy is less
than the value of the additional benefit achieved. A nega-
tive net monetary benefit implies that an intervention
should be rejected, as its costs are higher than the value of
the benefit achieved [22]. We have drawn Cost Effective-
ness Acceptability Curves (CEACs) by plotting the propor-
tion of the cost and effect pairs that are cost effective for a
range of values of Willingness To Pay (WTP).
Scenario analysis
The life span of Argus II Retinal Prosthesis is expected to
be the lifetime of the patient. For this reason our base case
model was undertaken over a 25 year time horizon. To test
the cost-effectiveness of Argus II Retinal Prosthesis in al-
ternative scenarios, the model was run for two different
time horizons of 20 years and 10 years. In addition, a con-
servative scenario analysis was undertaken where we also
ran our model in a scenario where costs were assumed to
remain constant across all Markov health states, i.e. equiva-
lent to the costs incurred by the legally blind RP patients
in spite of improved visual acuity.
Results
Base case results
Argus II Retinal Prosthesis fitted patients incurred a dis-
counted incremental cost of 42,455 Euros in comparison to
the patient given ‘CAU’ over the 25 years of time. Progres-
sive improvement in the visual acuity of the Argus II fitted
patients resulted in gain of 2.91 incremental QALYs (dis-
counted). Incremental cost-effectiveness ratio for Argus II
was calculated to be 14,603 Euros per QALY. Base case de-
terministic results are presented in Table 2.
Sensitivity analysis results
Probabilistic Sensitivity Analysis (PSA) showed that the
cost-effectiveness of Argus II was robust to change to all
key parameters within their plausible range. 1000 Monte
Carlo simulations resulted in a mean incremental cost for
Argus II of 42,018 Euros and mean incremental QALYs
of 2.90. The Probabilistic Incremental Cost-Effectiveness
Ratio (ICER) was estimated to be 14,482 Euros per QALY.
The mean of incremental costs and QALY values derived
from probabilistic simulations are presented in Table 2.
Table 2 Base case results
Deterministic Probabilistic
Intervention Disc costs Disc QALYs Disc costs Disc QALYs
Argus II € 243,549 7.34 243,511 7.35
CAU € 201,094 4.44 201,493 4.44
Increment € 42,455 2.91 42,018 2.90
ICERs € 14,603 € 14,482
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in the form of incremental cost-effectiveness planes in
Figure 2. In Figure 3 the CEACs show that Argus II be-
comes 100% cost effective at a WTP of 31000 Euros.Scenario analysis results
When the model was run for 20 years and 10 years Argus
II fitted patients yielded 2.49 and 1.35 discounted incre-
mental QALYs, for a discounted incremental cost of
49,128 and 67,140 Euros respectively. When costs across
all health states were constant then the deterministic In-
cremental Cost-effectiveness Ratios (ICER) for 25 years,
20 years and 10 years’ time horizons were 31,890, 33,842
and 68,096 Euros per QALY, respectively. Probabilistic
simulations also calculated ICER values very similar to the
deterministic ones. The detailed results of the scenario
analyses are presented in Table 3 and Table 4.Discussion
Argus II is a novel healthcare technology that restores vi-
sion in RP patients. Improvements in visual acuity are ex-
pected to lead to improvements in patient self-confidence,
decreasing their dependency, and to reduction in their de-
pression/anxiety and risk of falls.Figure 2 Incremental cost-effectiveness plane.To our knowledge, this is the first formal cost-
effectiveness analysis of a retinal prosthesis (Argus II)
for RP patients. Compared to usual care, we found the
Argus II device to be a cost effective intervention for RP pa-
tients from perspective of the healthcare payers. Over the
lifetime of RP patient, the ICER for Argus II was below the
published societal maximum willingness to pay thresholds
of Eurozone countries.
The safety study of the Argus II Retinal Prostesis System
has shown positive clinical results [13]. Since initial costs as-
sociated with the Argus II implantation may be regarded as
high, it was important to conduct an economic evaluation in
order to quantify the value for money of this technology
in long-term health gain and costs. Cost-effectiveness ana-
lysis determines the expected impact of alternative treat-
ment/care options. Cost-effectiveness results assist in
medical decision-making by quantifying the societal bene-
fits of a health technology against its costs and indicate
treatment/care option providing the best value for money.
We chose to perform the cost-utility analysis where out-
come measures are QALYs. This approach allows policy-
maker to compare the benefits of a health technology across
the health care areas due to a ‘common currency’ i.e. QALY.
Cost utility thresholds in many countries are either spe-
cified by authorities or are determined from pricing and
reimbursement decisions taken in these countries.
The acceptable range of this threshold in Canada is
CAN$ 20,000 - 100,000 per QALY [23], in United States
is US$50,000 per QALY [24], in England and Wales
is £20,000-30,000 per QALY [25,26], and in The
Netherlands is €20,000-80,000 per QALY [10]. Decision
analytic model for the Argus II Retinal Prosthesis System
predicted an ICER of 28,588 Euros per QALY for an RP
patient. This lifetime ICER value is well within the range
Figure 3 Cost-effectiveness acceptability curves (CEACs).
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in the countries inside and outside the Eurozone.
This retinal prosthesis is of considerable public health
interest as one of the most realistic approaches in cur-
rently untreatable retinal dystrophies. European policy to-
wards rare diseases defines RP a rare disease: affecting less
than one person in every 2000 persons. One of the objec-
tives defined by the EU Commission’s Directorate General
for Health and Consumer in article 12 of European ref-
erence network is to maximize the cost-effective use of
resources particularly in the area of rare diseases [27].
Products intended for the diagnosis, prevention orTable 3 Scenario analysis
Time horizon 20 years
Deterministic Probabilistic
Mean of 1000
simulations
Intervention Disc costs Disc QALYs Disc costs Disc QALYs
Argus II € 222,536 6.31 222,482 6.32
CAU € 173,408 3.82 173,752 3.83
Increment € 49,128 2.49 48,729 2.49
ICERs 19,744 19,602
Time horozon 10 years
Deterministic Probabilistic
Mean of 1000
simulations
Intervention Disc costs Disc QALYs Disc costs Disc QALYs
Argus II € 168,613 3.59 168,560 3.59
CAU € 101,473 2.24 101,674 2.24
Increment € 67,140 1.35 66,886 1.35
ICERs € 49,769 € 49,475treatment of a life threatening or chronically debilitating
rare disease are called as orphan medicinal products.
These products are often too expensive and have signifi-
cant impact on patient’s health care expenditure [28].
Therefore, orphan medical products are eligible for many
incentives as mentioned in the European Parliament and
Council Regulation (EC) No 141/2000 of 16 December
1999 on orphan medicinal products [29]. Orphan prod-
ucts are likely to have higher prices for modest effective-
ness and their ICERs are expected to be higher than the
cost effectiveness thresholds. It has been reported that so-
cietal considerations are taken in account while evaluating
orphan products as these products target medical condi-
tions with no alternative therapy. A higher cost effective-
ness threshold has been debated for products with high
social value [30]. However, economic evaluation of Argus
II Retinal Prosthesis System shows that it is a cost effective
intervention even for conventional Willingness To Pay
(WTP) thresholds. In various scenario analyses, higher
ICERs for shorter time horizons are due to high initial
costs of the device.
Markov model for the Argus II Retinal Prosthesis System
begins at the age of 46 years as most of the RP patients are
legally blind by this age. The model runs for 25 years to ex-
trapolate associated costs and health outcomes in RP pa-
tients in view of the shorter life expectancy of visually
impaired individuals. The productivity loss in RP patients is
difficult to fathom. Currently it would be too optimistic to
expect any change in RP patient’s productivity status after
successful Argus II implantation. Realistically, in RP pa-
tients improved quality of life and self-dependence should
be aimed by this device. On the other hand, Argus II is a
novel technological breakthrough incurring high initial cost
to the payers. Therefore, this cost-utility analysis for Argus
Table 4 Scenario analysis
Scenario analysis with constant costs for all Markov states
(no cost reduction)
Time horizon 25 years
Deterministic Probabilistic
Mean of 1000
simulations
Intervention Disc costs Disc QALYs Disc costs Disc QALYs
Argus II 293,807 7.34 294,083 7.35
CAU 201,094 4.44 200,995 4.43
Increment 92,712 2.91 93,088 2.93
ICERs 31,890 31,822
Time horizon 20 years
Deterministic Probabilistic
Mean of 1000
simulations
Intervention Disc costs Disc QALYs Disc costs Disc QALYs
Argus II 265,906 6.31 266,216 6.32
CAU 173,408 3.82 173,323 3.82
Increment 92,498 2.49 92,893 2.50
ICERs 37,174 37,117
Time horizon 10 years
Deterministic Probabilistic
Mean of 1000
simulations
Intervention Disc costs Disc QALYs Disc costs Disc QALYs
Argus II 193,336 3.59 193,730 3.59
CAU 101,473 2.24 101,423 2.23
Increment 91,864 1.35 92,307 1.36
ICERs 68,096 68,089
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health care payer’s perspective. It should be noted that the
Argus II subjects who participated in the clinical trial
did not receive specific rehabilitation after implantation
of their Argus II Retinal Prosthesis System. The analyses
presented in our article were based on FLORA study
data from two years of follow up of Argus II fitted pa-
tients. Based on this data an assessment of cost- effect-
iveness of Argus II in RP patients is suggestive of
significant QALY gain for these patients. Argus II fitted
patients are expected to get regular product support in
terms of software updates, special training and rehabili-
tation etc. The company Second Sight Medical Products
Inc. mandated a committee of experts in rehabilitation
specialized in low vision to develop a functional re-
habilitation program for both low vision and mobility.
This rehabilitation program will allow Argus II fitted
patients to integrate visual information in a complete
way. This program starts with teaching the basic skills
necessary to use the prosthesis, then identify thepersonal aims and objectives of the patients, and offer a
combination of conventional low vision, mobility re-
education, very specific for prosthetic vision, to help pa-
tients reach their objectives. This program will certainly
accelerate integration of the vision prosthesis and prob-
ably increase the functional utility of the Argus II Ret-
inal Prosthesis System for most patients. Furthermore,
an improvement has been observed over the results of
the clinical trial because of the refinement of the surgi-
cal procedure. At this point, it is probable that these im-
provements will translate into a substantial benefit.
Functional utility improvement and surgical refinement
would make Argus II device even more cost-effective in
future economic evaluations.
A single Argus II Retinal Prosthesis System was
explanted due to conjunctival erosion associated with
hypotonia. The patient was successfully explanted at
the 14th month postoperatively (the implant and the
retinal tack) without any complication. Argus II ex-
plantation is an expensive procedure leading to the re-
turn to the minimal light perception Markov state for a
RP patient. We have modeled explantation probabil-
ities for the life time of Argus II patients based on the
available data for two years. However, long term com-
plications such as explantation cannot be predicted ac-
curately and longer follow up data is required to model
such events. The model incorporates costs for Serious
Adverse Events (SAEs) in the first cycle only. As only
30% of the Argus II fitted patients had SAEs and 70%
of the SAEs occurred in 3 months and 82% of the SAEs
in 6 months after implantation. Similarly the utility re-
duction caused by SAEs is assigned to the patients ex-
periencing the SAEs in the first year of implantation.
Strength of this analysis is its potential transferability
as model inputs can be adapted to different settings.
Inter- or intra-country variations in costs or patient re-
ported outcomes can be incorporated into the model.
The model’s robustness was explored in terms of un-
certainty around the input parameters by varying point
estimates by 25% lower and 25% higher. Running prob-
abilistic simulations did validation of the model results.
The mean of 1000 probabilistic draws revealed ICERs
very similar to the deterministic values. This model
conforms to the principles of good practice for deci-
sion analytic models with use of transparent data and
modeling technique as per the guidelines laid by Inter-
national Society for Pharmacoeconomics and Outcome
Research (ISPOR) task force [10].
This study shares the general limitations of economic
modeling. The analysis presented in this paper was
based on the data from only 30 Argus II fitted patients
followed up for 24 months. This retinal prosthesis is a
novel technology that requires surgical intervention
and incurs considerable costs. Data from increased
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up in the coming years provides an opportunity re-
consolidate the results of our analysis. The costs and
utility values for our model are taken from comparable
patients. Future research should estimate costs and
elicit RP patients’ preferences to determine the utility
values in these patients at various visual acuity levels.
Conclusion
This economic evaluation concludes that Argus II Ret-
inal Prosthesis System is a cost-effective device to treat
RP patients. Argus II is the only licensed device avail-
able to restore some sight in these patients. The ICER
for Argus II falls below the societal willingness to pay in
most EU countries. This analysis numerically demon-
strates the health gain in terms of QALYs at an afford-
able cost in the Eurozone.
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